EMERGING-CTONG 1103 study compared the safety and efficacy of neoadjuvant erlotinib versus neoadjuvant chemotherapy in stage IIIA-N2 EGFR-mutated NSCLC (Zhong et al., 2019). Here, EGFR is linked to non-small cell lung carcinoma.